BIOT

•

Equity

L&G PHARMA BREAKTHROUGH UCITS ETF

TER (bps):

49

AUM (USD m):

65

ISIN:

IE00BF0H7608

Domicile:

Ireland

Share Class Currency:

USD

ESG:

No

Geographical Focus:

Global

As of:

19 May 2023

Climate Fund:

No

Benchmark

The Solactive Pharma Breakthrough Value Index aims to track the performance of a basket of stocks of companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. it uses a two-fold approach that is primarily based on the trend in the valuation of a company’s orphan drug portfolio and its overall revenue forecasts. The Index selects stocks that meet certain size and liquidity requirements.

PERFORMANCE

Powered byhttps://www.etfbook.com/ logo

RELATED ARTICLES

graphical user interface
Analysis

Thematic ETFs: Analysing performance drivers in 2021

The 12-month performance gap between the top and bottom ETFs on our list is 77.3%

Jamie Gordon

a man smiling for the picture
New Listing

LGIM launches Europe’s first digital payments ETF

PDAY tracks the Solactive Digital Payments index

Jamie Gordon

a man smiling for the picture
New Listing

LGIM launches Europe’s first hydrogen economy ETF

Tom Eckett

MOST READ

1
Analysis

How BlackRock came to dominate ETFs in Europe

Tom Eckett

2
Industry Updates

BlackRock to launch risk-based ETF savings plans with Bux

Theo Andrew

3
Industry Updates

One ETF has returned over 100% this year

Jamie Gordon

4
Analysis

US debt ceiling ‘crisis’: A buying opportunity in ultrashort Treasury ETFs

Tom Eckett

5
Industry Updates

State Street extends proxy voting powers to ETF and mutual fund investors

Jamie Gordon